Clinical Trial Update: Ruxolitinib Treatment in Inclusion Body Myositis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ruxolitinib for inclusion body myositis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inclusion Body Myositis

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Inclusion Body Myositis, Sporadic | Phase 2 | Status: RECRUITING